[VIRTUAL] Updated results from phase 1 study of CC-90011 in patients (pts) with solid tumors (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

[VIRTUAL] First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with Advanced non-small cell lung cancer (NSCLC)

[VIRTUAL] Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses followed by Dose Expansion of selinexor in Asian Patients with Advanced Solid Tumor Malignancies.

[VIRTUAL] CC-90010, a Reversible, Potent Oral Bromodomain and Extraterminal Inhibitor (BETi) in Patients (pts) with Advanced Solid Tumors (aSTs) and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Longer Follow-Up From Parts A & B and First Reporting of Part C of a Phase 1 Study

[VIRTUAL] Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: a phase 1b study in patients with advanced gastric cancer (RPT835GC1B)

[VIRTUAL] Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumors and superficial lesions

[VIRTUAL] A phase I study to evaluate safety, pharmacokinetics (PK), and preliminary efficacy of CYH33, a phosphatidylinositol 3-kinase α (PI3Kα) inhibitor, in patients (pts) with advanced solid tumors

[VIRTUAL] Immunohybridoma Cell-Based Vaccine for the Treatment of Patients with Castration-Resistant Prostate Cancer

[VIRTUAL] Safety, Tolerability and Preliminary Efficacy of Poziotinib with Twice Daily Strategy in EGFR/HER2 Exon 20 Mutant Non-small Cell Lung Cancer

[VIRTUAL] IND.236: A Canadian Cancer Trial Group (CCTG) Phase 1b trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)